Mergers & Acquisitions ·
On July 1, 2026, Cumberland Pharmaceuticals completed the sale of its FDA-approved products—including Acetadote…
CPIXCumberland Pharmaceuticals Inc
On July 1, 2026, Cumberland Pharmaceuticals completed the sale of its FDA-approved products—including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ—to Nuvo Pharmaceuticals (Ireland) DAC and affiliates of Apotex Inc. for $100 million in cash. The company retained its ifetroban product candidates and Cumberland Emerging Technologies, Inc. On June 29, 2026, the company used funds to repay approximately $5.3 million in outstanding obligations under a Revolving Credit Loan Agreement with Pinnacle Bank. Additionally, Chris T. Bitterman (VP Sales & Marketing) and James L. Herman (VP Trade & Distribution and Corporate Compliance Officer) will resign effective July 31, 2026, to join an Apotex affiliate. Cumberland Pharmaceuticals is a pharmaceutical company that develops and commercializes specialty medications.